ANKRD22 and non-small cell lung carcinoma: In order to investigate whether the expression of ANKRD22 was correlated with the clinicopathologic features of NSCLC patients, the samples were divided into three groups depending on the relative expression of ANKRD22 in C tissues compared with NC tissues: High (fold change ≥1.5, n = 28), Medium (1.5> fold change ≥1, n = 9) and Low (fold change <1, n = 10).